Drugs used in the Treatment of Peptic Ulcer Flashcards
GIT Control
Neuronal Myenteric Plexus Meissner Plexus Receive PS fibers from N.X Symp. fiber innervations: blood vessels, SM, some glandular cells
Neurons within Plexus = Enteric NS
Secretion of neuropeptides: ACh, NE, purines, 5HT
Hormonal
Endocrine Secretion-> Gastrin
Paracrine Secretion-> Histamine
Cells of Stomach
Mucous Neck Cells
Secrete mucous and bicarbonate
Parietal Cells
Secrete HCl and IF for absorption of B12, Ca2
Enterochromaffin Like Cells
Secrete histamine-> stimulate HCl secretion
Chief Cells
Secrete pepsinogen and gastric lipase
D Cells
Secrete somatostatin-> inhibits HCl secretion
G Cells
Secrete gastrin -> stimulate HCl secretion
Physiology of Gastric Acid Secretion
Around 2.5l/day
Phases:
Cephalic: taste and smell
Gastric: mechanical and chemical
Intestinal
Mechanism Neuronal control: N. X--> ACh Paracrine control: Enterochromaffin- like and mast cells: histamine Endocrine control: G cells-> gastrin
Regulation
Gastric contents increase secretion
protein, peptides, AA, milk, Ca salts
Neuronal factors
Increase: N.X and intramural plexi
Decrease: ACh-> decrease pH-> decrease HCl secre.
Hormonal Factors
Epinephrine: via b R-> increase gastric acid secretion
Somatostatin: reduce gastric acid secretion
Mechanism of Gastric Acid Secretion
Transporters req.
1) Cl/HCl antiporter
Cl into cell; HCl from cell-> plasma
2) Cl/K Cotransporter
Cl and K from cell into lumen
3) K/H ATPase
H from cell into lumen (created by carbonic anhydrase)
K from lumen into cell
Pathological Conditions
Erosive and ulcerative disease of upper GIT
GERD
Acute peptic ulcer: due to drugs (NSAIDs, steroids,
alcohol)
Chronic peptic ulcer: disturbance between aggressive
factors and protective factors
Zollinger Ellison Syndrome (ZES)
Gastrin producing tumor
Therapy of Acid Related GIT Diseases
Basic Principles
Inhibition of pain
Helping ulcer heal
Prevent ulcer recurrence
Drug Categories
Inhibition of Acid Secretion
Neutralising Gastric Acid
Increasing Resistance of Mucosa
Neutralising Gastric Acid
Antacids Definition Factors on which effects depend on Categorisation Clinical use Formulations
Are weak bases
Form salts with HCl-> decrease acidity
At pH>4 pepsin activity decreases
Mucosal PG and Bicarbonate secretion increases
Effects depend on Solubility in stomach Physiological effect Chemical activity Time of presence in stomach
Categorisation
Systemic: also water soluble at alkali pH-> absorbed
from intestines; can cause metabolic alkalosis
Non Systemic: formation of non water soluble salts in
intestine-> no absorption and influence on blood pH
Clinical Use
Good effect on duodenal ulcer
Poor effect on gastric ulcer
GERD: adjuvant th
Formulation
Tablet
Solution
Gel
Neutralising Gastric Acid
Antacids: Drug Names
NaHCO3 (Na Citrate)
CaCO3
MgO, Mg(OH)2, MgCO3
Al(OH)2
Neutralising Gastric Acid
Antacids: NaHCO3
(SYSTEMIC)
Fast effect
CO2 producing : decreases pyloric spasms-> faster
gastric emptying; but abdominal discomfort
SE in high doses
Na can cause oedema and hypertension
Milk alkali syndrome: when combo with milk: headache
dizziness, vomiting, constipation, Ca stones
Drug Interactions
Increase pH and motility in GIT-> decrease absorption
of Iron, Digoxin, Oral Anticoagulants, ABs
Neutralising Gastric Acid
Antacids: CaCO3
DON’T admin long term
Ca increases gastrin secretion and directly stimulates parietal cells-> increased acid production
Combo with a lot of milk-> milk alkali syndrome
Neutralising Gastric Acid
Antacids: MgO, Mg(OH)2, MgCO3
MgO and Mg(OH)2: fast neutralising action
NaCO3: slower, not freq. used
SE
laxative (osmotic): combo with Al(OH)3
Hypermagnesia in renal dysfunction: bradycardia
Neutralising Gastric Acid
Antacids: Al(OH)3
Weak neutralising-> slow onset and weak effect
AlCl3 salt forms gel like protective layer on injured mucosa
–> Neutralising + direct protection
SE Obstipation (combo with Mg compound antacid) Hyperphosphatemia in renal failure (forms insoluble phosphate salt in bowels) Weakness Osteomalacia Absorbed AI--> encephalopathy Chelates of drugs
Inhibition of Acid Secretion
Drug Groups
Competitive Antagonist H2
Muscarine R Antagonist
PPI
Other Anti Secretory Agents
Inhibition of Acid Secretion
Competitive Antagonist H2 MoA SE Pharmacokinetics Clinical Uses
MoA
Inhibits HCl secretion in stomach (parietal cells)
Reduces histamine and partially ACh induced gastrin
secretion
Decrease volume of gastric juice, H+ and pepsin
secretion
SE (minimal)
Diarrhoea, muscle pain, skin rash
Cimetidine reduces androgens–> reduces sex.
function, gynecomastia
Also is a major CYP450 inhibitor!
Pharmacokinetics
Good oral absorption
T1/2: 1-3 hrs; once a day enough as can use high dose
Renal elimination
Clinical Uses
Duodenal ulcer: healing and post healed ulcer:
preventative dose at 1/2 th dose
Gastric ulcer: healing and post healed ulcer:
preventative dose at 1/2 th dose
GERD and ZES: high dose
H. Pylori disease